Skip to content
Subscribe

Biotech lobbying dollars have secured market for genetically modified foods, study suggests

Published:

A new study has analyzed the lobbying activities of biotech companies and food patent holders since 1999. While the findings aren't surprising, they are enlightening as to why regulatory agencies and the U.S. Congress have shown the biotechnology industry such statutory favoritism.

“The food and agriculture biotechnology industry has been flexing its financial political muscle to ease the regulatory oversight of genetically modified foods,” say the authors in a report issued by Food & Water Watch.

They continue:

“Lobbying efforts for some of these firms and groups have included approval of cloned food and genetically engineered food, animals and livestock. Companies are also fighting to eliminate or prevent labeling on genetically modified foods in the United States and preventing other countries from regulating genetically modified foods. These efforts have dovetailed with lobbying to tighten intellectual property law protections over patented seeds and animals in attempts to further benefit the biotech industry.”

According to data compiled by Food & Water Watch, the 50 largest biotech companies and the top-two agrochemical trade associations have spent more than $572 million in campaign contributions over the last decade. Their report states that biotech interests:

“have hired a bevy of well-connected lobbying shops — including at least 13 former members of Congress and over 300 former congressional and White House staffers — to promote genetically modified food and agricultural products.”

Here are some more of their findings:

The top food and agricultural biotechnology firms spent more than $547 million lobbying Congress since 1999 as lobbying expenditures and PAC contributions to biotech-friendly advocacy groups rose twofold, from $35.0 million in 1999 to $71.0 million in 2009.

In 2010 alone, these firms employed over 100 lobbying companies as well as their own in-house lobbyists.

These biotechnology interests donated $22.4 million to congressional candidates between 1999 and July 2010, averaging about $2 million a year.

The effectiveness of the “hush-money” doled out by the Biotechnology Industry Organization – the special interest lobby for the industry – is apparent when one considers the disconnect between the sentiments of a vast majority of Americans towards GMOs and those of a few, unelected bureaucrats at the U.S. Food and Drug Administration who happen to set the food policy.

To illustrate this point, the authors of the study remind us that a 2010 Lake Research Partners poll found that 78 percent of Americans believe the FDA should not approve genetically engineered salmon. Two years earlier, the New York Times and CBS News conducted a poll which found that 87 percent of Americans support the labeling of any food product that contains genetically modified ingredients.

Even though awareness of the genetic modification process has caused some scientists to question the safety of such patented lifeforms, invoking an ever expanding body of research which confirms the danger they pose to our health (and the health of our environment), the FDA has stood behind every genetically altered product the industry has brought forth, ignoring numerous requests for the agency to study their potential risks, and roadblocking attempts by consumer organizations to pass laws to label GMO ingredients.

You can download the report here in PDF format.

Adhere to the IVN etiquette

By posting a comment, you agree to adhere to our etiquette rules: No partisan attacks, no personal attacks, substantiate your sources, no self-promotion.

Contact IVN

Questions about this article or our coverage? Send us a message. A free IVN member account is required.

Message sent

Thanks, we’ll review it and get back to you if needed.

Message not sent

Sorry, something went wrong. Please try again.

Sign in to send a message

Messages are tied to your IVN member account. Signing in is free and takes a few seconds.

Contact IVN

Questions about this article or our coverage? Send us a message. A free IVN member account is required.

Message sent

Thanks, we’ll review it and get back to you if needed.

Message not sent

Sorry, something went wrong. Please try again.

Sign in to send a message

Messages are tied to your IVN member account. Signing in is free and takes a few seconds.

Republish this article

Republishing guidelines

Republish IVN articles for free. Independent Voter News articles may be republished online or in print under a Creative Commons BY-NC-ND 4.0 license, on these terms:

  1. Credit the author and IVN. Keep the byline ("By Author Name, Independent Voter News") and the attribution note at the end, which links to the original.
  2. Keep the meaning. You may update time and place references and apply your house style. You may trim for length, as long as the cuts don't change the meaning or misrepresent the author. Keep the headline. Mark any additions as your own (for example "Additional reporting by ...").
  3. Translations are welcome. Translate faithfully, add "Translated from English by [your outlet]", and tell us at editor@ivn.us.
  4. Keep the links, including the link to the original article.
  5. Keep the tracking image. The HTML includes a 1-pixel image that counts readers on your page. It collects no personal information.
  6. Photos and illustrations. Images credited to IVN may be used with this article only. Images credited to others (AP, Getty, Unsplash, Wikimedia and so on) stay under their owners' terms. Secure the rights or switch "Include images" off.
  7. Don't sell it. You can't sell our articles or sell ads specifically against them. Your normal site advertising is fine.
  8. No implied endorsement. Don't suggest that IVN or the author endorses you, your candidates or your causes, or that donations to you support IVN.
  9. Keep labels. Opinion or analysis pieces keep that label.
  10. Point search engines to the original. Where your CMS allows, set the canonical URL to the original IVN article.
  11. No bulk or automated republishing, and don't submit our articles to aggregators (Apple News, Google News, MSN) as your own.
  12. Corrections and removals. Update your copy when we correct it, and remove it promptly if we ask. We'll contact you at the email you give us.
  13. Questions or print republication: editor@ivn.us.

IVN staff: fill in who you're inviting above, then create the invite.

Preparing the article

Biotech lobbying dollars have secured market for genetically modified foods, study suggests

Choose a format
  • HTML
  • Email HTML
  • Markdown
  • Formatted (.docx)
  • Plain text
  • WordPress blocks
  • PDF
Choose a platform

Photos credited to others need their owners' permission.

To for

Republishing somewhere else? Questions? editor@ivn.us